Reflex Testing Menu



Comprehensive molecular profiling from Caris Life Sciences® assesses DNA, RNA, and proteins with multiple technologies including next-generation sequencing (whole exome sequencing [WES] for DNA, whole transcriptome sequencing [WTS] for RNA), PyroSeq, immunohistochemistry (IHC), and *in situ* hybridization (ISH) to reveal a more comprehensive molecular blueprint to guide precise and individualized treatment decisions. This approach provides multiple reflex options to alternative technologies/methods in order to better optimize limited tissue samples and provide critical results. The information below provides examples of reflex testing for Caris molecular profiling.

Reflex Test	Tumor Types
Chromogenic in situ Hybridization	
EBER when EBV by WES is positive	All tumor types except Head & Neck, Esophagogastric Junction Carcinoma, Gastric Adenocarcinoma and CUP
HER2 CISH when HER2 IHC is equivocal	Breast Carcinoma, Cholangiocarcinoma, Colorectal Adenocarcinoma, Small Intestinal Malignancies (NOTE: HER2 IHC is not automatically run on all tumor types)
HPV CISH to confirm p16 IHC	Head & Neck
mmunohistochemistry	
BRAF V600E IHC when BRAF by WES is QNS/Indeterminate (by tumor type)	All solid tumors
EGFR L858R and EGFR ex19del IHCs when EGFR by WES is QNS/Indeterminate	NSCLC
ROS1 IHC when ROS1 Fusion Analysis by WTS is QNS/Indeterminate	NSCLC
TRK A/B/C IHC when NTRK 1, 2, and/or 3 Fusion Analysis by WTS is QNS/Indeterminate (by tumor type)	All solid tumors
HER2 IHC when HER2 CNA is amplified	All tumor types
MMR IHC when MSI is Indeterminate (by tumor type)	Bladder Cancer – Non-urothelial, Bladder Cancer – Urothelial, Breast Carcinoma, Cancer of Unknown Primary, Cervical Cancer, Cholangiocarcinoma, Colorectal Adenocarcinoma, Esophagogastric Junction Carcinoma, Extrahepatic Bile Duct Adenocarcinoma, Gastric Adenocarcinoma, Glioblastoma, Kidney Cancer, Low Grade Glioma, Neuroendocrine Tumors, Non Epithelial Ovarian Cancer, Ovarian Surface Epithelial Carcinomas, Pancreatic Adenocarcinoma, Prostatic Adenocarcinoma, Small Intestinal Malignancies, Uterine Serous Carcinoma, Uterine Neoplasms-Endometrial Carcinoma
Pyrosequencing	
MGMT Methylation	Glioma

Tests vary by tumor type and tissue sample quality and quantity. Before ordering testing services, please refer to the profile menu online (www.CarisLifeSciences.com) to view the most up-to-date listing of biomarkers that will be performed.

CNA: Copy Number Alteration (DNA)

MSI: Micro-satellite Instability

MMR: Mis-match Repair

